A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Ablative fractional laser‐assisted photodynamic therapy for lentigo maligna : a prospective pilot study (2020)


Räsänen, J.E., Neittaanmäki, N., Jeskanen, L., Pölönen, I., Snellman, E., & Grönroos, M. (2020). Ablative fractional laser‐assisted photodynamic therapy for lentigo maligna : a prospective pilot study. Journal of the European Academy of Dermatology and Venereology, 34(3), 510-517. https://doi.org/10.1111/jdv.15925


JYU-tekijät tai -toimittajat


Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajatRäsänen, J.E.; Neittaanmäki, N.; Jeskanen, L.; Pölönen, I.; Snellman, E.; Grönroos, M.

Lehti tai sarjaJournal of the European Academy of Dermatology and Venereology

ISSN0926-9959

eISSN1468-3083

Julkaisuvuosi2020

Volyymi34

Lehden numero3

Artikkelin sivunumerot510-517

KustantajaWiley-Blackwell Publishing Ltd.

JulkaisumaaBritannia

Julkaisun kielienglanti

DOIhttps://doi.org/10.1111/jdv.15925

Julkaisun avoin saatavuusEi avoin

Julkaisukanavan avoin saatavuus

Julkaisu on rinnakkaistallennettu (JYX)https://jyx.jyu.fi/handle/123456789/65412


Tiivistelmä

Background
Lentigo maligna (LM) is an in‐situ form of melanoma carrying a risk of progression to invasive lentigo maligna melanoma (LMM). LM poses a clinical challenge, with subclinical extension and high recurrence rates after incomplete surgery. Alternative treatment methods have been investigated with varying results. Photodynamic therapy (PDT) with methylaminolaevulinate (MAL) has already proved promising in this respect.

Objectives
To investigate the efficacy of ablative fractional laser (AFL)‐assisted PDT with 5‐aminolaevulinic acid nanoemulsion (BF‐200 ALA) for treating LM.

Methods
In this non‐sponsored, prospective pilot study ten histologically verified LMs were treated with AFL‐assisted PDT three times at two week intervals using a light dose of 90 J/cm2 per treatment session. Local anaesthesia with ropivacain was used. Four weeks after the last PDT treatment the lesions were treated surgically with a wide excision and sent for histopathological examination. The primary outcome was complete histopathological clearance of the LM from the surgical specimen. Patient‐reported pain during illumination and the severity of the skin reaction after the PDT treatments were monitored as secondary outcomes.

Results
The complete histopathological clearance rate was 7 out of 10 LMs (70%). The pain during illumination was tolerable, with the mean pain scores for the PDT sessions on a visual assessment scale ranging from 2.9 to 3.8. Some severe skin reactions occurred during the treatment period, however.

Conclusions
AFL‐assisted PDT showed moderate efficacy in terms of histological clearance. It could constitute an alternative treatment for lentigo maligna but due to the side‐effects it should only be considered in inoperable cases.


YSO-asiasanatfotodynaaminen hoitolaserhoitomelanooma

Vapaat asiasanatlentigo maligna; photodynamic therapy; ablative fractional laser; 5-aminolaevulinic acid nanoemulsion; BF-200 ALA


Liittyvät organisaatiot


OKM-raportointiKyllä

Raportointivuosi2020

JUFO-taso1


Viimeisin päivitys 2024-25-03 klo 19:46